{"disease":{"id":"residual-disease","name":"residual disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04466059","title":"Better Leukemia Diagnostics Through AI (BELUGA)","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"Munich Leukemia Laboratory","has_results":false},{"nct_id":"NCT06763302","title":"NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1220,"lead_sponsor_name":"The Children's Hospital of Zhejiang University School of Medicine","has_results":false},{"nct_id":"NCT06930807","title":"Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06230185","title":"CtDNA Based MRD Testing for NAC Monitoring in TNBC","phase":"","overall_status":"RECRUITING","enrollment_count":422,"lead_sponsor_name":"Personalis Inc.","has_results":false},{"nct_id":"NCT07350824","title":"Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":276,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT06404593","title":"Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases","phase":"","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT06323148","title":"Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":226,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06134375","title":"A Study of Tetrathiomolybdate (TM) Plus Capecitabine","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":204,"lead_sponsor_name":"Dartmouth-Hitchcock Medical Center","has_results":false},{"nct_id":"NCT06000306","title":"MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse","phase":"","overall_status":"COMPLETED","enrollment_count":192,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT05117879","title":"R0 Resection Rate Between CSP, cEMR and hEMR for 1-2 cm Colorectal SSLs","phase":"NA","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT07134088","title":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT07291921","title":"To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07413146","title":"Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT02520427","title":"A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":95,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT07264010","title":"Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":87,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT06109233","title":"A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"FengYan Jin","has_results":false},{"nct_id":"NCT06595966","title":"Exploratory Research on Constructing a Computational Biological Model Based on NGS for MRD After Breast Cancer Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07069595","title":"PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06287814","title":"French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)","phase":"","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT05735717","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT06536959","title":"VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":67,"lead_sponsor_name":"Beijing 302 Hospital","has_results":false},{"nct_id":"NCT06941987","title":"Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":66,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT06867146","title":"MRD in PAAD Adjuvant Therapy","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06936345","title":"Effective Treatments for Dizziness After BPPV: A Clinical Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"Medipol University","has_results":false},{"nct_id":"NCT05137860","title":"Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":56,"lead_sponsor_name":"Hospital General de Mexico","has_results":false},{"nct_id":"NCT05952661","title":"Minimally Residual of Esophageal Cancer 001","phase":"","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Hebei Medical University Fourth Hospital","has_results":false},{"nct_id":"NCT03233854","title":"CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":56,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT04541277","title":"Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":55,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT05362942","title":"Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":52,"lead_sponsor_name":"Beijing 302 Hospital","has_results":false},{"nct_id":"NCT04062266","title":"AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05969938","title":"Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"WeiWei Xiao","has_results":false},{"nct_id":"NCT05900583","title":"Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT05603156","title":"A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive","phase":"NA","overall_status":"UNKNOWN","enrollment_count":46,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06358430","title":"Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05460195","title":"Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT03516279","title":"Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT03297528","title":"Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06287749","title":"French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)","phase":"","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT05429320","title":"A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03189576","title":"Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases","phase":"NA","overall_status":"UNKNOWN","enrollment_count":37,"lead_sponsor_name":"Tampere University Hospital","has_results":false},{"nct_id":"NCT03494569","title":"Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":36,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT02458014","title":"Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03192397","title":"Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT03093207","title":"Omega-3 Fatty Acids Plus Low-dose Aspirin Daily Supplementation in Surgical Therapy to Treat Aggressive Periodontitis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Universidade Estadual Paulista Júlio de Mesquita Filho","has_results":true},{"nct_id":"NCT03241940","title":"Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT02159495","title":"Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":31,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT06287723","title":"French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT02529813","title":"CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05093192","title":"Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia","phase":"NA","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"University of Bath","has_results":false},{"nct_id":"NCT04853017","title":"A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Elicio Therapeutics","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}